TheraTech Inc., 417 Wakara Way, a company developing controlled drug-release technology, and Pfizer Inc., Groton, Conn., have extended their joint research and development project on transdermal patches for two years.
The local company will continue to evaluate selected Pfizer compounds and develop prototype patches for clinical studies on those compounds for which transdermal delivery seems appropriate.Pfizer and TheraTech began their joint project in June 1992. Since that time, TheraTech has evaluated 12 Pfizer compounds and produced supplies for clinical trials of two compounds.
Pfizer retains worldwide marketing rights to all products developed by the collaboration, while TheraTech will manufacture the patches and receive royalties on the sales of the products. Pfizer will fund TheraTech product development as well as make additional other payments.